BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 7779838)

  • 1. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
    Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
    Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occurrence of post-transplant lymphoproliferative disorders among over thousand adult recipients: any role for hepatitis C infection?
    Burra P; Buda A; Livi U; Rigotti P; Zanus G; Calabrese F; Caforio A; Menin C; Canova D; Farinati F; Luciana Aversa SM
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1065-70. PubMed ID: 16957512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment.
    Muti G; Cantoni S; Oreste P; Klersy C; Gini G; Rossi V; D'Avanzo G; Comoli P; Baldanti F; Montillo M; Nosari A; Morra E;
    Haematologica; 2002 Jan; 87(1):67-77. PubMed ID: 11801467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus infection in heart and heart-lung transplant recipients: incidence and clinical impact.
    Gray J; Wreghitt TG; Pavel P; Smyth RL; Parameshwar J; Stewart S; Cary N; Large S; Wallwork J
    J Heart Lung Transplant; 1995; 14(4):640-6. PubMed ID: 7578169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression.
    Armitage JM; Kormos RL; Stuart RS; Fricker FJ; Griffith BP; Nalesnik M; Hardesty RL; Dummer JS
    J Heart Lung Transplant; 1991; 10(6):877-86; discussion 886-7. PubMed ID: 1661607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttransplantation lymphoproliferative disorder in liver recipients: characteristics, management, and outcome.
    Ben-Ari Z; Amlot P; Lachmanan SR; Tur-Kaspa R; Rolles K; Burroughs AK
    Liver Transpl Surg; 1999 May; 5(3):184-91. PubMed ID: 10226108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Post-transplant lymphoproliferative disorders in renal transplantation: two decades of experience].
    Franco A; Jiménez L; Sillero C; Trigueros M; González D; Alcaraz E; Olivares J
    Nefrologia; 2010; 30(6):669-75. PubMed ID: 21113217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of Epstein-Barr virus acquisition and the course of posttransplantation lymphoproliferative disorder in children.
    Wu JF; Ho MC; Ni YH; Chen HL; Lu CY; Hsu HY; Lee PH; Chang MH
    Transplantation; 2009 Mar; 87(5):758-62. PubMed ID: 19295323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Uribe M; Hunter B; Alba A; Calabrán L; Flores L; Soto P; Herzog C
    Transplant Proc; 2009; 41(6):2679-81. PubMed ID: 19716000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoplastic disorders after pediatric heart transplantation.
    Bernstein D; Baum D; Berry G; Dahl G; Weiss L; Starnes VA; Gamberg P; Stinson EB
    Circulation; 1993 Nov; 88(5 Pt 2):II230-7. PubMed ID: 8222159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience.
    Muchtar E; Kramer MR; Vidal L; Ram R; Gurion R; Rosenblat Y; Bakal I; Shpilberg O
    Transplantation; 2013 Oct; 96(7):657-63. PubMed ID: 23823652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
    Humar A; Hébert D; Davies HD; Humar A; Stephens D; O'Doherty B; Allen U
    Transplantation; 2006 Mar; 81(6):856-61. PubMed ID: 16570008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients.
    Shahinian VB; Muirhead N; Jevnikar AM; Leckie SH; Khakhar AK; Luke PP; Rizkalla KS; Hollomby DJ; House AA
    Transplantation; 2003 Mar; 75(6):851-6. PubMed ID: 12660514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area.
    Cuellar-Rodriguez J; Avery RK; Lard M; Budev M; Gordon SM; Shrestha NK; van Duin D; Oethinger M; Mawhorter SD
    Clin Infect Dis; 2009 Sep; 49(5):710-6. PubMed ID: 19635026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenotonsillar hypertrophy and Epstein-Barr virus in pediatric organ transplant recipients.
    Shapiro NL; Strocker AM
    Laryngoscope; 2001 Jun; 111(6):997-1001. PubMed ID: 11404611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients.
    Zangwill SD; Hsu DT; Kichuk MR; Garvin JH; Stolar CJ; Haddad J; Stylianos S; Michler RE; Chadburn A; Knowles DM; Addonizio LJ
    J Heart Lung Transplant; 1998 Dec; 17(12):1161-6. PubMed ID: 9883755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.